Compugen reported $-7.67M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Arca Biopharma USD -31.82M 2.24M Mar/2026
aTyr Pharma USD -153K 24.71M Mar/2026
Bio Path USD -270K 706K Mar/2026
Brainstorm Cell Therapeutics USD -2.13M 21K Mar/2026
Cara Therapeutics USD -6.8M 1.28M Mar/2026
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD -7.67M 64.51M Mar/2026
Immunic USD -19.3M 6.28M Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
RedHill Biopharma USD -1.54M 0 Jun/2024
TherapeuticsMD USD -1.09M 356K Jun/2024